The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Path to IND for Biologics Delivers Phase I Clinical Trial Material in as few as 9 months*
Fact Sheet
The pressure to file an IND makes accelerated Phase I safety testing a priority. With the Path to IND for biologics, Thermo Fisher Scientific can help deliver your large molecule drug substance for First-in-Human studies in as little as 9 months* from the start of transfection.
Now you can meet important milestones—such as filing for IND—or secure additional funding with all the confidence your project needs and, we can supply.
*Terms and Conditions: Titer levels provided are estimates based on third party results and may vary depending on molecule type or other factors. Timeline from DNA to drug product and start of clinical trials for all path to IND for biologics options may vary depending on molecule type or other factors and are estimates to be finalized after third party cell line development dates are available and confirmed. 9-month timeline will incur additional risk.
